Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy Real-World Effectiveness and Safety in Chinese Adults with HIV-1 Infection
CTR20210120Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Feb 2021; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20210120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210120.